<p>Pharmaron (03759.HK) announced its 2025 annual results, with revenue of RMB 14.095 billion, an increase of 14.8% year-on-year; gross profit of RMB 4.857 billion, an increase of 17.1%. It recorded a net profit of RMB 1.664 billion, a decline of 7.2%, with earnings per share of 94.43 cents. The final dividend remains at 20 cents</p>

159849

588130

300759

<p>Pharmaron announced its 2025 annual performance, with revenue of 14.095 billion RMB (same below), an increase of 14.8% year-on-year; gross profit of 4.857 billion RMB, an increase of 17.1%. It recorded a net profit of 1.664 billion RMB, a decline of 7.2%, with earnings per share of 0.9443 RMB. The final dividend remains at 0.20 RMB</p>

AASTOCKS

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Pharmaron

E Fund Hang Seng SCHK Innovative Drug ETF

Guotai CSI Bio-medicine ETF

E Fund CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC CSI Biotechnology Theme ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

"Performance" Pharmaron's annual net profit is 1.664 billion RMB, down 7.2%, with a final dividend of 20 cents